Should I buy or sell Harpoon Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HARP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HARP, but not buy additional shares or sell existing shares. View HARP analyst ratings or view top-rated stocks .

What is Harpoon Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1 year target prices for Harpoon Therapeutics' stock. Their HARP share price targets range from $23.00 to $40.00. On average, they anticipate the company's stock price to reach $27.25 in the next year. This suggests a possible upside of 18.4% from the stock's current price. View analysts price targets for HARP or view top-rated stocks among Wall Street analysts .

How have HARP shares performed in 2024?

Harpoon Therapeutics' stock was trading at $11.37 on January 1st, 2024. Since then, HARP shares have increased by 102.4% and is now trading at $23.01. View the best growth stocks for 2024 here .

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share for the quarter, missing the consensus estimate of ($4.70) by $0.80. The business earned $4.09 million during the quarter, compared to analyst estimates of $11.06 million. Harpoon Therapeutics had a negative net margin of 81.68% and a negative trailing twelve-month return on equity of 893.55%.

When did Harpoon Therapeutics' stock split?

Shares of Harpoon Therapeutics reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com . Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , Alector (ALEC) , Precision BioSciences (DTIL) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Kaleido Biosciences (KLDO) , NVIDIA (NVDA) , Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD) .

When did Harpoon Therapeutics IPO?

Harpoon Therapeutics (HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HARP

Harpoon Therapeutics (HARP) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free HARP Stock Alerts

$23.01

0.00 (0.00%)

(As of 03/11/2024)

Compare

Today's Range: $23.01
▼
$23.01
50-Day Range: $22.33
▼
$23.01
52-Week Range: $3.11
▼
$23.21

Volume: N/A
Average Volume: 1.52 million shs
Market Capitalization: $389.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.25

Get Harpoon Therapeutics alerts:

Harpoon Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 18.4% Upside
$27.25 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.61
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$492.14 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.49) to ($4.56) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.56 out of 5 stars

Medical Sector

797th out of 929 stocks

Biotechnology Industry

20th out of 28 stocks

2.2

Analyst's Opinion

Consensus Rating
Harpoon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Harpoon Therapeutics has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for HARP.

0.0

Dividend Strength

Dividend Yield
Harpoon Therapeutics does not currently pay a dividend.
Dividend Growth
Harpoon Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Harpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Harpoon Therapeutics is -0.61.

1.4

News and Social Media Coverage

News Sentiment
Harpoon Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Harpoon Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for HARP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Harpoon Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harpoon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $492,135,715.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.49) to ($4.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harpoon Therapeutics has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Porter & Company

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

To get all the details of this controversial tech – click here now.

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection.

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

HARP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HARP Stock News Headlines

April 14, 2024 | americanbankingnews.com

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Given Consensus Recommendation of "Hold" by Analysts

March 16, 2024 | finance.yahoo.com

HARP Sep 2024 20.000 put

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 16, 2024 | finance.yahoo.com

HARP Apr 2024 20.000 put

March 13, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)

March 12, 2024 | msn.com

Merck completes acquisition of Harpoon Therapeutics

March 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)

March 6, 2024 | msn.com

Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

February 27, 2024 | msn.com

Citigroup Downgrades Harpoon Therapeutics (HARP)

February 26, 2024 | markets.businessinsider.com

Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics

February 24, 2024 | realmoney.thestreet.com

Harpoon Therapeutics just downgraded at Citi, here's why

February 23, 2024 | usnews.com

Fate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers Say

February 23, 2024 | msn.com

Merck wins EU backing for Keytruda use in resectable lung cancer

February 23, 2024 | finance.yahoo.com

HARPOON THERAPEUTICS (5HTA.BE)

February 23, 2024 | finance.yahoo.com

Harpoon Therapeutics Inc. (5HTA.SG)

February 22, 2024 | benzinga.com

Stock (HARP), Short Interest Report

February 13, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)

February 1, 2024 | msn.com

Merck Hasn't Even Closed Its Last Buyout, But It's Already Hunting For The Next Deal

January 30, 2024 | finance.yahoo.com

While private equity firms own 20% of Harpoon Therapeutics, Inc. (NASDAQ:HARP), retail investors are its largest shareholders with 36% ownership

January 19, 2024 | finanznachrichten.de

Arix Bioscience PLC: Financial update on Harpoon Therapeutics acquisition by Merck (MSD)

January 16, 2024 | markets.businessinsider.com

Peeling Back The Layers: Exploring Harpoon Therapeutics Through Analyst Insights

January 11, 2024 | baystreet.ca

Merck Stock Gains After Snatching Harpoon Therapeutics

January 9, 2024 | msn.com

Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio

January 9, 2024 | finance.yahoo.com

Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout

January 8, 2024 | investorplace.com

Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?

January 8, 2024 | markets.businessinsider.com

Merck In Talks To Acquire Harpoon Therapeutics: Reports

See More Headlines

Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2023
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:HARP
CUSIP: N/A
CIK: 1708493
Web: www.harpoontx.com
Phone: (650) 443-7400
Fax: N/A
Employees: 53
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.25
High Stock Price Target: $40.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +18.4%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-67,730,000.00
Net Margins: -81.68%
Pretax Margin: -81.67%
Return on Equity: -893.55%
Return on Assets: -45.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.89
Quick Ratio: 1.89

Sales & Book Value

Annual Sales: $37.34 million
Price / Sales: 10.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.63 per share
Price / Book: 14.12

Miscellaneous

Outstanding Shares: 16,932,000
Free Float: 14,054,000
Market Cap: $389.61 million
Optionable: Optionable
Beta: 2.11

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Ms. Julie M. Eastland M.B.A. (Age 60)
President, CEO, Secretary & Director
Comp: $910.77k
Dr. Luke N. Walker M.D. (Age 52)
Chief Medical Officer
Comp: $424.43k
Mr. Michael Eric Faerm (Age 57)
Interim Chief Financial Officer
Dr. Chatan Charan Ph.D.
Senior Vice President of Product Development, Technical & Manufacturing Operations
Mr. James B. Bucher J.D. (Age 58)
Chief Legal Officer
Ms. Wendy Chang
Chief People Officer
Dr. Banmeet Anand Ph.D.
Senior Vice President of Translational Medicine
Mr. Haibo Wang
Senior Vice President of Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HARP Stock Analysis - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HARP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HARP, but not buy additional shares or sell existing shares.
View HARP analyst ratings or view top-rated stocks.
What is Harpoon Therapeutics' stock price target for 2024?: 6 Wall Street analysts have issued 1 year target prices for Harpoon Therapeutics' stock. Their HARP share price targets range from $23.00 to $40.00. On average, they anticipate the company's stock price to reach $27.25 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for HARP or view top-rated stocks among Wall Street analysts.
How have HARP shares performed in 2024?: Harpoon Therapeutics' stock was trading at $11.37 on January 1st, 2024. Since then, HARP shares have increased by 102.4% and is now trading at $23.01.
View the best growth stocks for 2024 here.
How were Harpoon Therapeutics' earnings last quarter?: Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share for the quarter, missing the consensus estimate of ($4.70) by $0.80. The business earned $4.09 million during the quarter, compared to analyst estimates of $11.06 million. Harpoon Therapeutics had a negative net margin of 81.68% and a negative trailing twelve-month return on equity of 893.55%.
When did Harpoon Therapeutics' stock split?: Shares of Harpoon Therapeutics reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?: 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.
What other stocks do shareholders of Harpoon Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).
When did Harpoon Therapeutics IPO?: Harpoon Therapeutics (HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.
How do I buy shares of Harpoon Therapeutics?: Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HARP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Harpoon Therapeutics (HARP) Stock Price, News & Analysis

Harpoon Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Harpoon Therapeutics Stock (NASDAQ:HARP)

HARP Stock Price History

HARP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

HARP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™